6 withdrawn. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Withdrawn 6 |
| Phase 1 | 2 | Withdrawn 2 |
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapy for Progressive and/or Refractory Hematologic Malignancies TAPA-pulsed DC vaccine - Cancer, Hematologic Malignancies | Phase 1 / Phase 2 | Withdrawn | Kiromic BioPharma Inc. | 2017-07-28 | 2018-08-28 | |
| Consolidation Therapy in Patients With Hematologic Malignancies TAPA-pulsed DC vaccine - Cancer, Hematologic Malignancies | Phase 1 / Phase 2 | Withdrawn | Kiromic BioPharma Inc. | 2017-07-28 | 2019-10-14 | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant T Regulatory cells, Fludarabine, Cyclophosphamide - Hematologic Malignancies | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2016-06-01 | 2017-12-02 | |
| Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies ceritinib - Hematologic Malignancies | Phase 2 | Withdrawn | Anne Beaven, MD | 2015-05-01 | 2017-02-01 | |
| Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation TXA127 - Hematologic Malignancies | Phase 2 | Withdrawn | Tarix Pharmaceuticals | 2013-12-01 | 2016-08-31 | |
| Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation TXA127 - Hematologic Malignancies | Phase 2 | Withdrawn | Tarix Pharmaceuticals | 2013-12-01 | 2016-08-31 |
Hematologic Neoplasms (6) · Mucositis (2) · Neoplasms (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Prolymphocytic (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Hematologic Diseases (6) · Hemic and Lymphatic Diseases (6) · Neoplasms by Site (6) · Neoplasms (4) · Digestive System Diseases (2) · Gastroenteritis (2) · Gastrointestinal Diseases (2) · Immune System Diseases (2) · Mouth Diseases (2) · Stomatognathic Diseases (2) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Cardiovascular Diseases (1) · Chronic Disease (1) · DNA Virus Infections (1)
angiotensin I (1-7) (2) · Cyclophosphamide (1) · Whole-Body Irradiation (1) · ceritinib (1) · fludarabine (1) · fludarabine phosphate (1)
Kiromic BioPharma Inc. (2) · Tarix Pharmaceuticals (2) · Anne Beaven, MD (1) · Masonic Cancer Center, University of Minnesota (1)
United States (5)
Anne Beaven, MD (1) · Claudio Brunstein, MD, PhD (1) · Edmund K Waller, MD,PhD,FACP (1) · Mary J Laughlin, MD (1) · Naval G Daver, MD (1)
P01CA065493 (1)